Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 47.37 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.504 million which beat the analyst consensus estimate of $1.379 million by 9.08 percent. This is a 25.65 percent increase over sales of $1.197 million the same period last year.